The term glaucoma describes a heterogeneous group of optic neuropathies that lead to optic nerve atrophy and permanent loss of vision, affecting over 67 million subjects worldwide [1] . Since glaucoma rates rise exponentially with age, more glaucoma cases are expected in the future as the western population gets older [2] . The disease is insidious. Affected patients frequently have no symptoms, especially in the initial stages. When detected early, most cases can be successfully treated with medications, laser treatment, or surgery.
The term glaucoma describes a heterogeneous group of optic neuropathies that lead to optic nerve atrophy and permanent loss of vision, affecting over 67 million subjects worldwide [1] . Since glaucoma rates rise exponentially with age, more glaucoma cases are expected in the future as the western population gets older [2] . The disease is insidious. Affected patients frequently have no symptoms, especially in the initial stages. When detected early, most cases can be successfully treated with medications, laser treatment, or surgery.
The hereditary forms of glaucoma are genetically heterogeneous. Primary open angle glaucoma (POAG) of adult onset is the most common form of glaucoma, representing approximately half of all cases. Normal tension glaucoma (NTG) is an important subtype of POAG, accounting for approximately 20-50% of all POAG cases. Patients with NTG show intraocular pressures that are within the statistical normal range of the population (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .
Despite the rather high prevalence and heritable nature of POAG, identification of causative genes has proven to be difficult. Though at least 20 loci have been linked to POAG [3] , only two disease-causing genes for POAG have been identified until lately. A number of studies confirmed that about 4% of POAG cases show mutations in the MYOC gene [4] . Although mutations in the optineurin gene (OPTN) were initially reported in 16.7% of families with hereditary POAG [5] , several other studies have indicated that OPTN sequence variants are only a rare cause of POAG or NTG [6] [7] [8] . Recently, a new locus for POAG (GLC1G) and the disease-causing gene (WDR36) have been identified by Monemi and coworkers [9] . In their study, mutation analysis of WDR36 in 130 unrelated affected individuals revealed a total of 25 allelic variants. The function of WDR36 and its role in the normal ocular physiology and glaucoma is still unclear, but WDR36 has been identified as being involved in T cell activation [10] .
The purpose of this study was to determine the prevalence of WDR36 sequence variants in a cohort of unrelated German patients with NTG.
METHODS

Screening and selection of patients:
The study population comprised a cohort of 112 unrelated white patients with NTG that included 67 women and 45 men. Their age range was 14-84 years with a mean age of 62.3±15.3. All study patients were part of a group of 289 patients that had been previously clinically investigated at the University Eye Hospital in Wuerzburg [11] . Selected from this group for molecular genetic analysis were 112 patients who had been followed long-term.This was to ensure diagnosis of NTG with a maximum of certainty. Patients have been screened for MYOC and OPTN mutations in a previous study [12] . Glaucoma was defined by the following strict criteria: (1) the presence of typical glaucomatous optic neuropathy with compatible visual field loss (according to Aulhorn classification) [13] ; (2) open drainage angles on gonioscopy; and (3) absence of a secondary cause for glaucomatous optic neuropathy, such as a previously elevated intraocular pressure (IOP) after trauma, a period of steroid administration, or uveitis. Patients also did not have evidence of high myopia or congenital ocular abnormality, and had no other cause than glaucoma for disk changes and visual 
Detection of nucleotide variants by denaturing high performance liquid chromatography:
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Individual exons of the WDR36 gene were amplified by polymerase chain reaction (PCR) using appropriate amplification protocols. with the profile of wild-type DNA fragments. Samples with aberrant profiles were sequenced. Mutation detection by direct sequencing: PCR fragments were purified by ExoSAP-IT treatment (USB, Cleveland, OH), sequenced using Big Dye Termination chemistry (Applied Biosystems, Weiterstadt, Germany) and products separated on a DNA capillary sequencer (ABI 3100 Genetic Analyzer).
Detection of nucleotide variants by restriction fragment length polymorphism analysis: A 361 bp PCR product encompassing exon 8 of the WDR36 gene was digested with 1 U HpyCH4III restriction enzyme (NEB, Beverly, MA). The N355S missense change resulted in the gain of an HpyCH4III restriction site that, upon cleavage of the amplicon, produced two DNA fragments of 251 bp and 110 bp.
A 450 bp PCR product encompassing exon 11 of the WDR36 gene was digested with 1 U TseI restriction enzyme (NEB). The A449T missense change resulted in the loss of a TseI restriction site. Wild-type sequences were cleaved into two fragments of 229 bp and 221 bp.
A 450 bp PCR product encompassing exon 13 of the WDR36 gene was digested with 1 U TaqI restriction enzyme (NEB). The R529Q missense change resulted in the loss of a TaqI restriction site. Wild-type sequences were cleaved into two fragments of 232 bp and 218 bp.
A 282 bp PCR product encompassing exon 17 of the WDR36 gene was digested with 1 U BglI restriction enzyme (NEB). The D658G missense change resulted in the gain of a BglI restriction site that, upon cleavage of the amplicon, produced two DNA fragments of 233 bp and 49 bp. Restriction digests were analyzed on a 4% agarose gel.
RESULTS
We screened the complete coding sequences plus flanking intron/UTR sequences of the WDR36 gene by denaturing high performance liquid chromatography (DHPLC) and subsequent sequencing in 112 patients with NTG. In addition, we performed RFLP analysis for four known sequence alterations that were judged in a previous study to be disease-causing mutations [9] . Of those four, we were able to identify three by RFLP analysis as well as with DHPLC and subsequent sequencing, namely A449T (found in two subjects), R529Q (found in one subject), and D658G (found in one subject), respectively ( Figure 1 and Table 3 ). We were not able to detect any of these changes in 50 controls using DHPLC and RFLP analysis.
DHPLC analysis and subsequent sequencing also identified four additional nonsynonymous nucleotide changes, namely P31T, D33E, A163V, and H212P which were not present in 50 controls. The latter three have already been described [9, 14] , whereas this is the first report of P31T. 
TABLE 3. FREQUENCIES, LOCALIZATION, AND PUTATIVE FUNCTIONAL EFFECT OF IDENTIFIED WDR36 SEQUENCE VARIANTS
Sequence variants identified in the WDR36 gene. The "Nucleotide change" column is based on GenBank accession number NM_139281 and the "Prediction of functional effect" column is according to PolyPhen. In the table, ND refers to not determined. DHPLC screening and subsequent sequencing also revealed several synonymous polymorphisms (Q197Q, K564K, V714V, V727V) as well as 11 intronic alterations (Table 3) . Neither a deletion/insertion nor a sequence alteration close to splice donor/acceptor sites change was found.
Four patients harbored a potentially causative mutation in the OPTN gene or MYOC gene as was found in a previous study [12] . These patients did not show sequence variants in the WDR36 gene.
DISCUSSION
This study describes mutational screening in the WDR36 gene in a large cohort of German patients with the NTG subtype of POAG. The primary aim of our study was to evaluate the prevalence of previously described mutations classified as disease causing [9] . Therefore, two different mutation-screening techniques (DHPLC and RFLP) were used to make sure that all four mutations (N355S, A449T, R529Q, and D658G) were detected.
None of our patients had the N355S mutation described by Monemi and coworkers [9] . Instead, we identified one patient who harbored the R529Q mutation that has already been described in two independent studies [9, 14] . According to the prediction program PolyPhen, this particular change lies in a highly conserved region and possibly has a damaging effect (Table 3 and Figure 2 ). In addition, we identified two patients with NTG who carried the A449T sequence variant. This mutation is not part of a known protein motif. It was not conserved and is therefore benign according to the PolyPhen prediction. The D658G mutation noted in 3 out of 272 sporadic cases in the Monemi study was observed in one patient in the NTG group. In the former study this change was shown to be not present in 238 controls, whereas a case-control study on this particular variant in Australian patients demonstrated an equal distribution in both patients and controls [15] . Although this mutation leads to a conservative exchange of two polar and acidic residues, PolyPhen predicts this change to be probably damaging due to the high conservation between species (Figure 2) .
In addition to the aforedescribed disease-causing mutations, we were able to identify sequence variants previously classified as disease-susceptibility mutations, namely D33E, A163V, and H212P [9, 14] . We also noted one nonsynonymous nucleotide change (P31E) that has not been reported before. It was found in one patient in the NTG group and was not present in the control population. As the proline residue is not conserved between species (data not shown) and is not located in any known protein motif of WDR36, this change is probably benign.
Although our patient and control cohort numbers were too small for a statistical analysis to determine whether the sequence variants we identified might be related to the disease, our results indicate that sequence variants of the WDR36 gene already described to be disease-causing are only rare causes of unrelated NTG in the German population.
Apart from the findings of our study concerning WDR36 sequence variants, we observed that the results of the DHPLC screening in those exons that harbored already described mutations were consistent with the results of RFLP analysis (Figure 1) . In addition, we identified several exonic and intronic polymorphisms by using DHPLC and subsequent sequencing. Therefore we reason that screening of the WDR36 gene with DHPLC gives rather reliable results compared with the hands-on time. Direct sequencing still represents the gold standard in mutation screening, and other screening mechanisms, such as DHPLC, are not as sensitive. Nevertheless, we are convinced that our screening procedure using DHPLC and RFLP gave comparable good detection rates. From our study it seems likely that DHPLC gives false positive results rather than false negative ones. Yet, we have to consider that we may have missed some nucleotide changes that could be associated with the NTG phenotype in our patients. In addition, as we only screened for mutations in exonic and flanking intron sequences, it is possible that a proportion of our patients carry mutations in the promoter region or in other regulatory sequences of WDR36. Screening with either DHPLC or direct sequencing does not reveal gross insertions or deletions that may be responsible for the phenotype.
Our study indicates that WDR36 sequence variants are only rare causes of unrelated NTG in the German population. In a previous study [12] , we showed this also holds true for the other two POAG-associated genes MYOC and OPTN. As early diagnosis is critical for successful treatment of glaucoma, defining the genetic basis of hereditary forms of glaucoma is an important step towards a presymptomatic screening of people at risk. However, a routine genetic testing for the three known POAG-associated genes seems to be of limited value due to the low prevalence of disease-causing mutations.
A considerable number of studies dealing with the genetics of glaucoma have shown that only a small proportion of glaucoma cases are due to monogenic forms. The vast majority of cases are inherited as a complex trait. Therefore, genome-wide association studies might be a better strategy to use in defining genetic profiles for those at risk for developing glaucoma.
